• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Clene Inc.

    5/16/25 4:11:24 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    SD 1 clnn20250429_sd.htm FORM SD clnn20250429_sd.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549


    FORM SD

    SPECIALIZED DISCLOSURE REPORT


    CLENE INC.

    (Exact name of registrant as specified in its charter)


     

    Delaware

    001-39834

    85-2828339

    (State or other jurisdiction of

    (Commission File Number)

    (I.R.S. Employer
    incorporation or organization)   Identification No.)
         

    6550 South Millrock Drive, Suite G50

    Salt Lake City, Utah

      84121
    (Address of principal executive offices)   (Zip code)

     

    Jerry Miraglia, (443) 273-1645

    (Name and telephone number, including area code,

    of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2024.

     

     

     

     

    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    This Specialized Disclosure Form of Clene Inc. (the “Company”) is being filed in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024 (the “Relevant Period”). The Rule imposes disclosure requirements of certain information when a company manufactures or contracts to manufacture products for which Conflict Minerals are necessary to the functionality or production of those products. The term “Conflict Minerals” means columbite-tantalite (coltan), cassiterite, gold, wolframite, or their derivatives, which are limited to tantalum, tin, and tungsten, or any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of the Congo or an adjoining country (the “Covered Countries”).

     

    During the Relevant Period, the Company determined a Conflict Mineral, gold, was necessary to the functionality or production of its products.

     

    Conflict Minerals Disclosure

     

    The Company conducted a reasonable country of origin inquiry regarding the origin of gold used in its products during the Relevant Period. The Company’s reasonable country of origin inquiry consisted of (i) identifying all suppliers of gold to the Company, which consisted of one supplier during the Relevant Period, (ii) requesting that each gold supplier complete the Responsible Minerals Initiative (“RMI”) Conflict Minerals Reporting Template (“CMRT”), a standardized reporting template developed by RMI to collect sourcing information on Conflict Minerals, and (iii) reviewing the supplier response and CMRT and performing any follow-up procedures or clarification as deemed necessary. The Company received a response from its gold supplier which included 45 other smelters that it sourced gold from during the Relevant Period, which the Company cross-referenced against the RMI Conformant Smelter List without exception. The RMI Conformant Smelter List is a list of smelters who have successfully completed an independent, third-party audit assessment of smelter and refiner management systems and sourcing practices for responsible mineral procurement against Responsible Minerals Assurance Process standards. Based on the information obtained from these procedures, the Company has no reason to believe that any of the gold sourced during the Relevant Period originated in any of the Covered Countries. Therefore, in accordance with the Rule, the Company is not required to conduct a due diligence process or file a Conflict Minerals Report with respect to such conflict minerals. The Company’s only obligation is to briefly describe both the reasonable country of origin inquiry it undertook and the corresponding results as set forth hereinabove.

     

    This Conflict Minerals Disclosure is publicly available on the Company’s website, located at https://invest.clene.com/financial-information/sec-filings. The information contained in or accessible from the Company’s website is not incorporated into this Form SD and should not be considered part of this Form SD.

     

    Item 1.02 Exhibit

     

    Not applicable.

     

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01 Resource Extraction Issuer Disclosure and Report

     

    Not applicable.

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

    Not applicable.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

     

    CLENE INC.

     

     

     

     

     

    Date: May 16, 2025

    By:

    /s/ Robert Etherington

     

     

     

    Robert Etherington

     

     

     

    President and Chief Executive Officer

     

     

    2
     
    Get the next $CLNN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Clene Appoints Neurology Expert to Executive Team

    SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

    3/16/23 9:46:10 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces New Chief Financial Officer Morgan Brown

    SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

    2/1/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

    SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

    8/5/21 4:01:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:14:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matlin David J

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:12:43 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiernan Matthew

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:11:22 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/2/24 12:58:21 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:06 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clene downgraded by Oppenheimer

    Oppenheimer downgraded Clene from Outperform to Perform

    10/4/22 8:58:30 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Clene with a new price target

    H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

    7/18/22 7:19:07 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Clene with a new price target

    Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

    5/2/22 9:11:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Financials

    Live finance-specific insights

    View All

    Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

    The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

    10/3/22 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

    SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

    9/30/22 4:12:25 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

    CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie

    8/15/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

    Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosingThe Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALSA Type B end-of-Phase 2 FDA meeting has been scheduled in the third quarter of 2025 to discuss the MS clinical development programCash and cash equivalents of $7.3 million as of June 30, 2025, together

    8/14/25 8:38:15 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Present at the Emerging Growth Conference

    SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 20, 2025Time of Presentation: 2:20 p.m. ETFormat: Corporate update with Q&A A webcast of the presentation will be available on the "Events" section of the Clene website. Alternatively, one can register for and view

    8/13/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    SEC Filings

    View All

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    8/14/25 8:41:09 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Clene Inc.

    10-Q - Clene Inc. (0001822791) (Filer)

    8/14/25 8:02:45 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    7/3/25 4:36:43 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Clene Inc.

    SC 13D/A - Clene Inc. (0001822791) (Subject)

    10/2/24 4:38:44 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care